30 closest matches · ranked by relevance
Systemic Mastocytosis, Aggressive (ASM) · Leukemia, Mast Cell · Hematological Non-mast Cell Lineage Disease (AHNMD)
Primary: Subjects With Clinical Response [Partial Response (PR) + Complete Response (CR)] — 25 participants
Leukemia
Primary: Percentage of Participants With Overall Response Rate (ORR) — 59.6 Percentage of participants — p=<0.001
Advanced Systemic Mastocytosis · Aggressive Systemic Mastocytosis · Systemic Mastocytosis With an Associated Hematologic Neoplasm
Primary: Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on…
Systemic Mastocytosis
Primary: Number of Participants With Objective Response — 0 Participants
Aggressive Systemic Mastocytosis · Mast Cell Leukemia · Systemic Mastocytosis
Primary: Overall Response Rate (ORR) Per Consensus International Response Criteria (Rate of Complete or Partial Remissions or Clinical Improvement) — 0 participants
Indolent Systemic Mastocytosis
Primary: Percent Change in Quality of Life (QoL) Using Mastocytosis Quality of Life Questionnaire (MC-QoL) — 38.98; 33.02 percentage of change in quality of life — p=0.7740
Chronic Myelomonocytic Leukemia · Chronic Myeloid Leukemia · Polycythemia Vera
Primary: Number of Participants With a Complete Response (CR) — 0; 0; 2; 0 participants
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome
Primary: Percentage of Participants With Objective Response (OR) — 0 Percentage of participants
Asthma · Mastocytosis · Mast Cell Activation Syndrome
Primary: Mast Cell Activation Test Results for Validation Group — 6; 2; 0; 4 Participants
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005
Sarcoma · Gastrointestinal Stromal Tumors
Primary: 2-year Relapse Free Survival Rate — 93.6 percentage of participants
Mycosis Fungoides · Sezary Syndrome
Primary: Efficacy of Nonmyeloablative Preparative Regimen — 4 Participants
Systemic Sclerosis
Primary: Improvement in the Modified Rodnan Skin Score — -6.6 units on a scale
Mucosal Melanoma · Acral/Lentiginous Melanoma · Chronically Sun Damaged Melanomas
Primary: Best Overall Response — 0; 0; 0; 7 participants
Myelofibrosis · Chronic Myelomonocytic Leukemia
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 6 participants
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 7 participants
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants
Chronic Myelogenous Leukemia · Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) · Hypereosinophilic Syndrome
Primary: Number of Participants With Major Cytogenetic Response (MCyR) — 191; 44; 22 Participants
Gastro Intestinal Stromal Tumor
Primary: Time to Next Treatment (TNT) — 26.7 months
Polycythemia Vera · Thrombocythemia
Primary: Number of Participants With Best Overall Response — 0; 3; 6 Participants
Alveolitis · Systemic Sclerosis
Primary: Treatment-related Adverse Events — 5 participants
Multiple Myeloma
Primary: Number of Patients Removed From Study Treatment Due to Toxicities — 31 participants
Melanoma
Primary: Th1/Th2 Normalized Gene Expression — 1.029; 0.119; 0.074; 0.192 fold change
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic and Organ Response — 11; 7; 18 participants
Juvenile Myelomonocytic Leukemia
Primary: Determine Probability of Long-term Disease Free Survival in JMML — 67 Percentage of participants
Histiocytic Disorders
Primary: Best Overall Response — 21; 5; 3; 6 Participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic Response Rate — 55.9; 69.1 percentage of participants